Report Detail

Pharma & Healthcare Global Heart Failure Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

  • RnM4594476
  • |
  • 12 June, 2024
  • |
  • Global
  • |
  • 125 Pages
  • |
  • GIR (Global Info Research)
  • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Heart Failure Therapeutics market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.
Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The Global Info Research report includes an overview of the development of the Heart Failure Therapeutics industry chain, the market status of Hospital (Diagnosis, Prognosis), Clinic (Diagnosis, Prognosis), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Heart Failure Therapeutics.
Regionally, the report analyzes the Heart Failure Therapeutics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Heart Failure Therapeutics market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Heart Failure Therapeutics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Heart Failure Therapeutics industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Diagnosis, Prognosis).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Heart Failure Therapeutics market.
Regional Analysis: The report involves examining the Heart Failure Therapeutics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Heart Failure Therapeutics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Heart Failure Therapeutics:
Company Analysis: Report covers individual Heart Failure Therapeutics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Heart Failure Therapeutics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to Heart Failure Therapeutics. It assesses the current state, advancements, and potential future developments in Heart Failure Therapeutics areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Heart Failure Therapeutics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Heart Failure Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Diagnosis
Prognosis
Treatment Options and Treatment Algorithm
Market segment by Application
Hospital
Clinic
Medical Research Organization
Market segment by players, this report covers
Bayer
Cynokinetics
Les Laboratoires Servier
Merck & Co.
Novartis
Procoralan
Bristol-Myers Squibb Company
Cardiorentis AG
CVie Therapeutics Limited
Orion Corporation
PhaseBio Pharmaceuticals
Market Segment by Product Type
B-Blockers
Calcium Channel Blockers
Cardiac Glycosides
Diuretics
Morphine
Vasodilators/Nitrates
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Heart Failure Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Heart Failure Therapeutics, with revenue, gross margin and global market share of Heart Failure Therapeutics from 2019 to 2024.
Chapter 3, the Heart Failure Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Heart Failure Therapeutics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Heart Failure Therapeutics.
Chapter 13, to describe Heart Failure Therapeutics research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Heart Failure Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Heart Failure Therapeutics by Type
    • 1.3.1 Overview: Global Heart Failure Therapeutics Market Size by Type: 2019 Versus 2023 Versus 2030
    • 1.3.2 Global Heart Failure Therapeutics Consumption Value Market Share by Type in 2023
    • 1.3.3 Diagnosis
    • 1.3.4 Prognosis
    • 1.3.5 Treatment Options and Treatment Algorithm
  • 1.4 Global Heart Failure Therapeutics Market by Application
    • 1.4.1 Overview: Global Heart Failure Therapeutics Market Size by Application: 2019 Versus 2023 Versus 2030
    • 1.4.2 Hospital
    • 1.4.3 Clinic
    • 1.4.4 Medical Research Organization
  • 1.5 Global Heart Failure Therapeutics Market Size & Forecast
  • 1.6 Global Heart Failure Therapeutics Market Size and Forecast by Region
    • 1.6.1 Global Heart Failure Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
    • 1.6.2 Global Heart Failure Therapeutics Market Size by Region, (2019-2030)
    • 1.6.3 North America Heart Failure Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.4 Europe Heart Failure Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.5 Asia-Pacific Heart Failure Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.6 South America Heart Failure Therapeutics Market Size and Prospect (2019-2030)
    • 1.6.7 Middle East and Africa Heart Failure Therapeutics Market Size and Prospect (2019-2030)

2 Company Profiles

  • 2.1 Bayer
    • 2.1.1 Bayer Details
    • 2.1.2 Bayer Major Business
    • 2.1.3 Bayer Heart Failure Therapeutics Product and Solutions
    • 2.1.4 Bayer Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.1.5 Bayer Recent Developments and Future Plans
  • 2.2 Cynokinetics
    • 2.2.1 Cynokinetics Details
    • 2.2.2 Cynokinetics Major Business
    • 2.2.3 Cynokinetics Heart Failure Therapeutics Product and Solutions
    • 2.2.4 Cynokinetics Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.2.5 Cynokinetics Recent Developments and Future Plans
  • 2.3 Les Laboratoires Servier
    • 2.3.1 Les Laboratoires Servier Details
    • 2.3.2 Les Laboratoires Servier Major Business
    • 2.3.3 Les Laboratoires Servier Heart Failure Therapeutics Product and Solutions
    • 2.3.4 Les Laboratoires Servier Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.3.5 Les Laboratoires Servier Recent Developments and Future Plans
  • 2.4 Merck & Co.
    • 2.4.1 Merck & Co. Details
    • 2.4.2 Merck & Co. Major Business
    • 2.4.3 Merck & Co. Heart Failure Therapeutics Product and Solutions
    • 2.4.4 Merck & Co. Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.4.5 Merck & Co. Recent Developments and Future Plans
  • 2.5 Novartis
    • 2.5.1 Novartis Details
    • 2.5.2 Novartis Major Business
    • 2.5.3 Novartis Heart Failure Therapeutics Product and Solutions
    • 2.5.4 Novartis Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.5.5 Novartis Recent Developments and Future Plans
  • 2.6 Procoralan
    • 2.6.1 Procoralan Details
    • 2.6.2 Procoralan Major Business
    • 2.6.3 Procoralan Heart Failure Therapeutics Product and Solutions
    • 2.6.4 Procoralan Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.6.5 Procoralan Recent Developments and Future Plans
  • 2.7 Bristol-Myers Squibb Company
    • 2.7.1 Bristol-Myers Squibb Company Details
    • 2.7.2 Bristol-Myers Squibb Company Major Business
    • 2.7.3 Bristol-Myers Squibb Company Heart Failure Therapeutics Product and Solutions
    • 2.7.4 Bristol-Myers Squibb Company Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.7.5 Bristol-Myers Squibb Company Recent Developments and Future Plans
  • 2.8 Cardiorentis AG
    • 2.8.1 Cardiorentis AG Details
    • 2.8.2 Cardiorentis AG Major Business
    • 2.8.3 Cardiorentis AG Heart Failure Therapeutics Product and Solutions
    • 2.8.4 Cardiorentis AG Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.8.5 Cardiorentis AG Recent Developments and Future Plans
  • 2.9 CVie Therapeutics Limited
    • 2.9.1 CVie Therapeutics Limited Details
    • 2.9.2 CVie Therapeutics Limited Major Business
    • 2.9.3 CVie Therapeutics Limited Heart Failure Therapeutics Product and Solutions
    • 2.9.4 CVie Therapeutics Limited Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.9.5 CVie Therapeutics Limited Recent Developments and Future Plans
  • 2.10 Orion Corporation
    • 2.10.1 Orion Corporation Details
    • 2.10.2 Orion Corporation Major Business
    • 2.10.3 Orion Corporation Heart Failure Therapeutics Product and Solutions
    • 2.10.4 Orion Corporation Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.10.5 Orion Corporation Recent Developments and Future Plans
  • 2.11 PhaseBio Pharmaceuticals
    • 2.11.1 PhaseBio Pharmaceuticals Details
    • 2.11.2 PhaseBio Pharmaceuticals Major Business
    • 2.11.3 PhaseBio Pharmaceuticals Heart Failure Therapeutics Product and Solutions
    • 2.11.4 PhaseBio Pharmaceuticals Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.11.5 PhaseBio Pharmaceuticals Recent Developments and Future Plans
  • 2.12 Market Segment by Product Type
    • 2.12.1 Market Segment by Product Type Details
    • 2.12.2 Market Segment by Product Type Major Business
    • 2.12.3 Market Segment by Product Type Heart Failure Therapeutics Product and Solutions
    • 2.12.4 Market Segment by Product Type Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.12.5 Market Segment by Product Type Recent Developments and Future Plans
  • 2.13 B-Blockers
    • 2.13.1 B-Blockers Details
    • 2.13.2 B-Blockers Major Business
    • 2.13.3 B-Blockers Heart Failure Therapeutics Product and Solutions
    • 2.13.4 B-Blockers Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.13.5 B-Blockers Recent Developments and Future Plans
  • 2.14 Calcium Channel Blockers
    • 2.14.1 Calcium Channel Blockers Details
    • 2.14.2 Calcium Channel Blockers Major Business
    • 2.14.3 Calcium Channel Blockers Heart Failure Therapeutics Product and Solutions
    • 2.14.4 Calcium Channel Blockers Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.14.5 Calcium Channel Blockers Recent Developments and Future Plans
  • 2.15 Cardiac Glycosides
    • 2.15.1 Cardiac Glycosides Details
    • 2.15.2 Cardiac Glycosides Major Business
    • 2.15.3 Cardiac Glycosides Heart Failure Therapeutics Product and Solutions
    • 2.15.4 Cardiac Glycosides Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.15.5 Cardiac Glycosides Recent Developments and Future Plans
  • 2.16 Diuretics
    • 2.16.1 Diuretics Details
    • 2.16.2 Diuretics Major Business
    • 2.16.3 Diuretics Heart Failure Therapeutics Product and Solutions
    • 2.16.4 Diuretics Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.16.5 Diuretics Recent Developments and Future Plans
  • 2.17 Morphine
    • 2.17.1 Morphine Details
    • 2.17.2 Morphine Major Business
    • 2.17.3 Morphine Heart Failure Therapeutics Product and Solutions
    • 2.17.4 Morphine Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.17.5 Morphine Recent Developments and Future Plans
  • 2.18 Vasodilators/Nitrates
    • 2.18.1 Vasodilators/Nitrates Details
    • 2.18.2 Vasodilators/Nitrates Major Business
    • 2.18.3 Vasodilators/Nitrates Heart Failure Therapeutics Product and Solutions
    • 2.18.4 Vasodilators/Nitrates Heart Failure Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
    • 2.18.5 Vasodilators/Nitrates Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Heart Failure Therapeutics Revenue and Share by Players (2019-2024)
  • 3.2 Market Share Analysis (2023)
    • 3.2.1 Market Share of Heart Failure Therapeutics by Company Revenue
    • 3.2.2 Top 3 Heart Failure Therapeutics Players Market Share in 2023
    • 3.2.3 Top 6 Heart Failure Therapeutics Players Market Share in 2023
  • 3.3 Heart Failure Therapeutics Market: Overall Company Footprint Analysis
    • 3.3.1 Heart Failure Therapeutics Market: Region Footprint
    • 3.3.2 Heart Failure Therapeutics Market: Company Product Type Footprint
    • 3.3.3 Heart Failure Therapeutics Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Heart Failure Therapeutics Consumption Value and Market Share by Type (2019-2024)
  • 4.2 Global Heart Failure Therapeutics Market Forecast by Type (2025-2030)

5 Market Size Segment by Application

  • 5.1 Global Heart Failure Therapeutics Consumption Value Market Share by Application (2019-2024)
  • 5.2 Global Heart Failure Therapeutics Market Forecast by Application (2025-2030)

6 North America

  • 6.1 North America Heart Failure Therapeutics Consumption Value by Type (2019-2030)
  • 6.2 North America Heart Failure Therapeutics Consumption Value by Application (2019-2030)
  • 6.3 North America Heart Failure Therapeutics Market Size by Country
    • 6.3.1 North America Heart Failure Therapeutics Consumption Value by Country (2019-2030)
    • 6.3.2 United States Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.3 Canada Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 6.3.4 Mexico Heart Failure Therapeutics Market Size and Forecast (2019-2030)

7 Europe

  • 7.1 Europe Heart Failure Therapeutics Consumption Value by Type (2019-2030)
  • 7.2 Europe Heart Failure Therapeutics Consumption Value by Application (2019-2030)
  • 7.3 Europe Heart Failure Therapeutics Market Size by Country
    • 7.3.1 Europe Heart Failure Therapeutics Consumption Value by Country (2019-2030)
    • 7.3.2 Germany Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.3 France Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.4 United Kingdom Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.5 Russia Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 7.3.6 Italy Heart Failure Therapeutics Market Size and Forecast (2019-2030)

8 Asia-Pacific

  • 8.1 Asia-Pacific Heart Failure Therapeutics Consumption Value by Type (2019-2030)
  • 8.2 Asia-Pacific Heart Failure Therapeutics Consumption Value by Application (2019-2030)
  • 8.3 Asia-Pacific Heart Failure Therapeutics Market Size by Region
    • 8.3.1 Asia-Pacific Heart Failure Therapeutics Consumption Value by Region (2019-2030)
    • 8.3.2 China Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.3 Japan Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.4 South Korea Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.5 India Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.6 Southeast Asia Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 8.3.7 Australia Heart Failure Therapeutics Market Size and Forecast (2019-2030)

9 South America

  • 9.1 South America Heart Failure Therapeutics Consumption Value by Type (2019-2030)
  • 9.2 South America Heart Failure Therapeutics Consumption Value by Application (2019-2030)
  • 9.3 South America Heart Failure Therapeutics Market Size by Country
    • 9.3.1 South America Heart Failure Therapeutics Consumption Value by Country (2019-2030)
    • 9.3.2 Brazil Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 9.3.3 Argentina Heart Failure Therapeutics Market Size and Forecast (2019-2030)

10 Middle East & Africa

  • 10.1 Middle East & Africa Heart Failure Therapeutics Consumption Value by Type (2019-2030)
  • 10.2 Middle East & Africa Heart Failure Therapeutics Consumption Value by Application (2019-2030)
  • 10.3 Middle East & Africa Heart Failure Therapeutics Market Size by Country
    • 10.3.1 Middle East & Africa Heart Failure Therapeutics Consumption Value by Country (2019-2030)
    • 10.3.2 Turkey Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.3 Saudi Arabia Heart Failure Therapeutics Market Size and Forecast (2019-2030)
    • 10.3.4 UAE Heart Failure Therapeutics Market Size and Forecast (2019-2030)

11 Market Dynamics

  • 11.1 Heart Failure Therapeutics Market Drivers
  • 11.2 Heart Failure Therapeutics Market Restraints
  • 11.3 Heart Failure Therapeutics Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Heart Failure Therapeutics Industry Chain
  • 12.2 Heart Failure Therapeutics Upstream Analysis
  • 12.3 Heart Failure Therapeutics Midstream Analysis
  • 12.4 Heart Failure Therapeutics Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Heart Failure Therapeutics. Industry analysis & Market Report on Heart Failure Therapeutics is a syndicated market report, published as Global Heart Failure Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2030. It is complete Research Study and Industry Analysis of Heart Failure Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    $3,480.00
    $5,220.00
    $6,960.00
    2,683.08
    4,024.62
    5,366.16
    3,194.64
    4,791.96
    6,389.28
    551,197.20
    826,795.80
    1,102,394.40
    290,719.20
    436,078.80
    581,438.40
    Credit card Logo

    Related Reports


    Reason to Buy

    Request for Sample of this report